NEW YORK, Jan. 28, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Tetraphase Pharmaceuticals Inc. (“Tetraphase”) (NASDAQ:TTPH) between March 5, 2015 and September 8, 2015. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. To get more information go to:
http://zlk.9nl.com/tetraphase-pharmaceuticals-ttph
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that Tetraphase and certain insiders issued materially false and misleading statements to investors. In particular, it is alleged that throughout the class period, Tetraphase made positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.
On September 8, 2015, the Company announced that the pivotal portion of its IGNITE2 phase 3 clinical trial of Eravacycline did not achieve its primary endpoint. Following this news, shares of Tetraphase fell from a close of $44.78 on September 8, 2015, to a close of $8.36 per share on September 10, 2015—a loss of more than 80% in market value.
If you suffered a loss in Tetraphase you have until March 28, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns
Ukrainian Drone Makers Target Japan and Asia Defense Market
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 



